From August 18th 2026, GtoPdb will require users to register to use the website. Please see our blog post for more information.

telisotuzumab vedotin   Click here for help

GtoPdb Ligand ID: 13908

Synonyms: ABBV-399 | ABBV399 | ABT-700-vcMMAE | Emrelis® | Teliso-V | telisotuzumab vedotin-tllv
Approved drug
telisotuzumab vedotin is an approved drug
Compound class: Antibody
Comment: Telisotuzumab vedotin (ABBV-399; ABT-700) is an antibody-drug conjugate (ADC). It is a conjugate of the anti-hepatocyte growth factor receptor (HGFR; c-Met) antibody ABT-700 and the cytotoxic microtubule inhibitor MMAE (or vedotin) [4]. It was designed for anti-tumour activity in malignancies with MET amplification and/or c-Met overexpression, and that express constitutive c-Met signalling or ligand-dependent activation of c-Met.
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
References
1. Blair HA. (2025)
Telisotuzumab Vedotin: First Approval.
Drugs, 85 (9): 1171-1176. [PMID:40736649]
2. Horinouchi H, Cho BC, Camidge DR, Goto K, Tomasini P, Li Y, Vasilopoulos A, Brunsdon P, Hoffman D, Shi W et al.. (2025)
Results from a phase Ib study of telisotuzumab vedotin in combination with osimertinib in patients with c-Met protein-overexpressing, EGFR-mutated locally advanced/metastatic non-small-cell lung cancer (NSCLC) after progression on prior osimertinib.
Ann Oncol, 36 (5): 583-591. [PMID:39805351]
3. Wang J, Anderson MG, Oleksijew A, Vaidya KS, Boghaert ER, Tucker L, Zhang Q, Han EK, Palma JP, Naumovski L et al.. (2017)
ABBV-399, a c-Met Antibody-Drug Conjugate that Targets Both MET-Amplified and c-Met-Overexpressing Tumors, Irrespective of MET Pathway Dependence.
Clin Cancer Res, 23 (4): 992-1000. [PMID:27573171]
4. Wang J, Goetsch L, Tucker L, Zhang Q, Gonzalez A, Vaidya KS, Oleksijew A, Boghaert E, Song M, Sokolova I et al.. (2016)
Anti-c-Met monoclonal antibody ABT-700 breaks oncogene addiction in tumors with MET amplification.
BMC Cancer, 16: 105. [PMID:26879245]